⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2237352 | 0.80 | — | — | |
| SCHEMBL3261233 | 0.75 | — | — | |
| SCHEMBL305702 | 0.75 | — | — | |
| SCHEMBL10299557 | 0.72 | — | — | |
| SCHEMBL4911960 | 0.70 | — | — | |
| SCHEMBL4908442 | 0.67 | — | — | |
| SCHEMBL6310576 | 0.65 | — | — | |
| SCHEMBL21539627 | 0.64 | SORT1 (0.35) | — | |
| SCHEMBL3263708 | 0.64 | — | — | |
| SCHEMBL22078527 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025054530-A1 | PYRIMIDINE-CONTAINING POLYCYCLIC DERIVATIVES AS KRAS G12D MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| CN-114008065-B | Glycyrrhetinic acid derivatives for the treatment of hyperkalemia | 阿德利克斯股份有限公司 | 2025-03-11 | — | — | CN | disclosed |
| US-20240209019-A1 | COMPOUNDS AND METHODS FOR TREATING HYPERKALEMIA | ARDELYX, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240209019-A1 | COMPOUNDS AND METHODS FOR TREATING HYPERKALEMIA | ARDELYX, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240209019-A1 | COMPOUNDS AND METHODS FOR TREATING HYPERKALEMIA | ARDELYX, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-11858959-B2 | Glycyrrhetinic acid derivatives for use in treating hyperkalemia | ARDELYX, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858959-B2 | Glycyrrhetinic acid derivatives for use in treating hyperkalemia | ARDELYX, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858959-B2 | Glycyrrhetinic acid derivatives for use in treating hyperkalemia | ARDELYX, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| EP-4234016-A2 | GLYCYRRHETINIC ACID DERIVATIVES FOR USE IN TREATING HYPERKALEMIA | Ardelyx, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4234016-A2 | GLYCYRRHETINIC ACID DERIVATIVES FOR USE IN TREATING HYPERKALEMIA | Ardelyx, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3921327-B1 | GLYCYRRHETINIC ACID DERIVATIVES FOR USE IN TREATING HYPERKALEMIA | ARDELYX INC (US) | 2023-04-05 | — | — | EP | disclosed |
| US-20220106354-A1 | GLYCYRRHETINIC ACID DERIVATIVES FOR USE IN TREATING HYPERKALEMIA | ARDELYX, INC. (US) | 2022-04-07 | — | — | US | disclosed |
| CN-114008065-A | Glycyrrhetinic acid derivatives for treating hyperkalemia | 阿德利克斯股份有限公司 | 2022-02-01 | — | — | CN | disclosed |
| EP-3921327-A1 | GLYCYRRHETINIC ACID DERIVATIVES FOR USE IN TREATING HYPERKALEMIA | Ardelyx, Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| WO-2020163642-A1 | GLYCYRRHETINIC ACID DERIVATIVES FOR USE IN TREATING HYPERKALEMIA | ARDELYX, INC. (US) | 2020-08-13 | — | — | WO | disclosed |
| WO-2020163642-A1 | GLYCYRRHETINIC ACID DERIVATIVES FOR USE IN TREATING HYPERKALEMIA | ARDELYX, INC. (US) | 2020-08-13 | — | — | WO | disclosed |
| EP-1740556-A1 | HETEROCYCLIC ANTI-VIRAL COMPOUNDS COMPRISING METABOLIZABLE MOIETIES AND THEIR USES | Rigel Pharmaceuticals, Inc. (US) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005097760-A1 | HETEROCYCLIC ANTI-VIRAL COMPOUNDS COMPRISING METABOLIZABLE MOIETIES AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2005-10-20 | — | — | WO | disclosed |